Meeting
2014 Gastrointestinal Cancers Symposium
Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in advanced pancreatic cancer patients.
Authors
Akira Shinohara
Division of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan
Akira Shinohara , Hiroyuki Okuyama , Akiko Kuwahara , Misaki Kobayashi , Hideaki Takahashi , Izumi Ohno , Satoshi Shimizu , Shuichi Mitsunaga , Shinichiro Saitoh , Masafumi Ikeda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 266)
DOI
10.1200/jco.2014.32.3_suppl.266
Abstract #
266
Poster Bd #
B39
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC.
First Author: Michael Haas
Poster
2017 Gastrointestinal Cancers Symposium
Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.
First Author: Weijia Fang
Poster
2017 Gastrointestinal Cancers Symposium
A phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
First Author: Boram Han
Poster
2012 Gastrointestinal Cancers Symposium
Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).
First Author: Krishna Soujanya Gunturu